<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03980977</url>
  </required_header>
  <id_info>
    <org_study_id>2017 A00266-47</org_study_id>
    <nct_id>NCT03980977</nct_id>
  </id_info>
  <brief_title>Unusual Toxicity Induced by Radiotherapy</brief_title>
  <acronym>CRYOTOX</acronym>
  <official_title>Collection of Biological Samples for Stydy of Unusual Toxicity Induced by Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de Lorraine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to evaluate the physiopathological knowledge of the different pathological
      manifestations associated with individual radiosensitivity, it seems essential to carry out
      this pilot study. It has agglomerated homogeneous tissue samples to identify new biomarkers
      for patient diagnosis and follow-up, and may predict the therapeutic response. These
      knowledge will help to treatment customization.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2018</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>skin fibroblast radiosensitivity</measure>
    <time_frame>2 to 3 months after skin biopsy</time_frame>
    <description>The number of residual double strand break at 24 hours (number of 53BP1 foci) after a dose of 2 Gy will be quantified with indirect immunofluorescence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tumor cells radiosensitivity</measure>
    <time_frame>2 to 3 months after tumor biopsy</time_frame>
    <description>The number of residual double strand break at 24 hours (number of 53BP1 foci) after a dose of 2 Gy will be quantified with indirect immunofluorescence</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>skin and/or tumor Biopsy and blood sample</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>skin biopsy</intervention_name>
    <description>skin biopsy will be taken under local anesthesia using a patch of lidocaine and prilocaine. In practice, during the skin biopsy, the skin must be cleaned with chlorhexidine or alcohol, to the exclusion of any other antiseptic. The biopsy will preferably be done with a dermatome (or &quot;punch&quot;, 12 G).</description>
    <arm_group_label>skin and/or tumor Biopsy and blood sample</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>tumor biopsy</intervention_name>
    <description>an additional tumor sample will be taken during programmed diagnostic procedure.</description>
    <arm_group_label>skin and/or tumor Biopsy and blood sample</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>blood sample will be taken for biological collection</description>
    <arm_group_label>skin and/or tumor Biopsy and blood sample</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Child or teenager aged 2 to &lt;18

          -  Man, Woman&gt; 18 years old

          -  Patient with one of these situations:

               -  Unusual toxicity in progress or after radiotherapy

               -  Indication of radiotherapy and suspicion of abnormal pathways of response to
                  ionizing radiation - constitutional (genetic disease) or acquired (systemic
                  disease) - which may generate unusual radioinduced toxicity

          -  Patient information and informed consent signed by the patient. For children and
             teenager : information to parents and obtaining informed consent

          -  Affiliation to a social security scheme.

        Exclusion Criteria:

          -  Contraindication for skin and / or tumoral biopsy

          -  Contraindication for blood sample of 2.5 ml

          -  Persons deprived of liberty or under supervision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean Louis MERLIN</last_name>
    <phone>033383598307</phone>
    <email>jl.merlin@nancy.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Priscillia TOSTI</last_name>
    <phone>0033383598657</phone>
    <email>p.tosti@nancy.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume VOGIN</last_name>
      <email>g.vogin@nancy.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 3, 2019</study_first_submitted>
  <study_first_submitted_qc>June 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>March 6, 2020</last_update_submitted>
  <last_update_submitted_qc>March 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unusual toxicity</keyword>
  <keyword>radiosensitivity</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>fibroblast cell</keyword>
  <keyword>indirect immunofluorescence test</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

